Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.530
-0.010 (-0.65%)
At close: Nov 4, 2024, 4:00 PM
1.520
-0.010 (-0.68%)
After-hours: Nov 4, 2024, 6:22 PM EST
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$1,660,094
Market Cap
66.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Hyperfine | 131 |
Prelude Therapeutics | 128 |
Owlet | 76 |
Boundless Bio | 72 |
Vivani Medical | 44 |
Zentek | 24 |
Entera Bio | 18 |
HeartBeam | 15 |
QNCX News
- 21 days ago - Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 2 months ago - Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex - Seeking Alpha
- 2 months ago - Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - Business Wire
- 2 months ago - Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire
- 4 months ago - Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Business Wire
- 5 months ago - Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - Business Wire
- 6 months ago - Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - Business Wire